These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1686755)

  • 1. Anxiolytic-like activity of R(+)- and S(-)-zacopride in mice.
    Young R; Johnson DN
    Eur J Pharmacol; 1991 Aug; 201(2-3):151-5. PubMed ID: 1686755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of routes of administration and time course effects of zacopride and buspirone in mice using an automated light/dark test.
    Young R; Johnson DN
    Pharmacol Biochem Behav; 1991 Dec; 40(4):733-7. PubMed ID: 1687761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interaction of R(+)- and S(-)-zacopride with PCPA to modify rodent aversive behaviour.
    Barnes NM; Costall B; Ge J; Kelly ME; Naylor RJ
    Eur J Pharmacol; 1992 Jul; 218(1):15-25. PubMed ID: 1356806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiles of interaction of R(+)/S(-)-zacopride and anxiolytic agents in a mouse model.
    Barnes NM; Cheng CH; Costall B; Ge J; Kelly ME; Naylor RJ
    Eur J Pharmacol; 1992 Jul; 218(1):91-100. PubMed ID: 1356807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced anxiolytic effect of zacopride enantiomers in diazepam-withdrawn rats.
    File SE; Andrews N
    Eur J Pharmacol; 1993 Jun; 237(1):127-30. PubMed ID: 8102974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The enantiomers of zacopride: an intra-species comparison of their potencies in functional and anxiolytic models.
    Bill DJ; Coleman J; Hallett I; Middlefell VC; Rhodes KF; Fletcher A
    Br J Pharmacol; 1995 Jul; 115(5):775-80. PubMed ID: 8548176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of potencies of 5-HT3 receptor antagonists at inhibiting aversive behavior to illumination and the von Bezold-Jarisch reflex in the mouse.
    Eglen RM; Lee CH; Khabbaz M; Fontana DJ; Daniels S; Kilfoil T; Wong EH
    Neuropharmacology; 1994 Feb; 33(2):227-34. PubMed ID: 8035908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the emetic and antiemetic properties of zacopride and its enantiomers.
    Sancilio LF; Pinkus LM; Jackson CB; Munson HR
    Eur J Pharmacol; 1991 Jan; 192(3):365-9. PubMed ID: 2055236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zacopride: anxiolytic profile in rodent and primate models of anxiety.
    Costall B; Domeney AM; Gerrard PA; Kelly ME; Naylor RJ
    J Pharm Pharmacol; 1988 Apr; 40(4):302-5. PubMed ID: 2900320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential modulation of extracellular levels of 5-hydroxytryptamine in the rat frontal cortex by (R)- and (S)-zacopride.
    Barnes NM; Cheng CH; Costall B; Ge J; Naylor RJ
    Br J Pharmacol; 1992 Sep; 107(1):233-9. PubMed ID: 1384906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The differential activities of R (+)- and S(-)-zacopride as 5-HT3 receptor antagonists.
    Barnes JM; Barnes NM; Costall B; Domeney AM; Johnson DN; Kelly ME; Munson HR; Naylor RJ; Young R
    Pharmacol Biochem Behav; 1990 Dec; 37(4):717-27. PubMed ID: 2128757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioural studies on WAY100289, a novel 5-HT3 receptor antagonist, in two animal models of anxiety.
    Bill DJ; Fletcher A; Glenn BD; Knight M
    Eur J Pharmacol; 1992 Aug; 218(2-3):327-34. PubMed ID: 1358637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of zacopride and BMY25801 (batanopride) on radiation-induced emesis and locomotor behavior in the ferret.
    King GL; Landauer MR
    J Pharmacol Exp Ther; 1990 Jun; 253(3):1026-33. PubMed ID: 2359014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agonist effects at putative central 5-HT4 receptors in rat hippocampus by R(+)- and S(-)-zacopride; no evidence for stereo-selectivity.
    Boddeke HW; Kalkman HO
    Neurosci Lett; 1992 Jan; 134(2):261-3. PubMed ID: 1589153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-HT3 receptor agonism may be responsible for the emetic effects of zacopride in the ferret.
    Middlefell VC; Price TL
    Br J Pharmacol; 1991 May; 103(1):1011-2. PubMed ID: 1831684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zacopride and its optical isomers produce stereoselective antagonism of a 2-methylserotonin discriminative stimulus.
    Young R; Glennon RA
    Eur J Pharmacol; 1992 Feb; 212(1):117-9. PubMed ID: 1555633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The (S)-isomer of [3H]zacopride labels 5-HT3 receptors with high affinity in rat brain.
    Waeber C; Pinkus LM; Palacios JM
    Eur J Pharmacol; 1990 Jun; 181(3):283-7. PubMed ID: 2384135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fully automated light/dark apparatus useful for comparing anxiolytic agents.
    Young R; Johnson DN
    Pharmacol Biochem Behav; 1991 Dec; 40(4):739-43. PubMed ID: 1687762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of stereoisomers of zacopride to analyze actions of 5-hydroxytryptamine on enteric neurons.
    Wade PR; Mawe GM; Branchek TA; Gershon MD
    Am J Physiol; 1991 Jan; 260(1 Pt 1):G80-90. PubMed ID: 1987811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potent 5-HT3 receptor antagonist (R)-zacopride labels an additional high affinity site in the central nervous system.
    Kidd E; Bouchelet de Vendegies I; Levy JC; Hamon M; Gozlan H
    Eur J Pharmacol; 1992 Jan; 211(1):133-6. PubMed ID: 1618262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.